Immunotherapy in India: How It Works, Costs, and Who Benefits (2026)

Key Takeaways

• Immunotherapy harnesses your immune system to fight cancer. In India, it costs ₹1-3 lakh per cycle, compared to ₹8-15 lakh globally.

What Is Immunotherapy and How Does It Work

Immunotherapy is a fundamentally different approach to cancer treatment. Instead of directly killing cancer cells like chemotherapy or radiation, immunotherapy teaches your immune system to recognize and attack cancer. Cancer cells survive by hiding from the immune system, using molecules like PD-L1 to tell immune cells not to attack. Immunotherapy drugs block these hiding signals, removing the cloak and exposing cancer to your immune system.

The most common immunotherapy drugs are PD-1 and PD-L1 inhibitors. PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab) work by releasing immune brakes on T-cells. PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) block the cancer’s ability to hide. Once these brakes are released, your T-cells recognize and destroy cancer cells. This approach works for many cancer types and is particularly effective in cancers with high tumor mutational burden or specific mutations.

Which Cancers Respond Best to Immunotherapy

Immunotherapy is FDA-approved and available in India for several cancers. Lung cancer, melanoma, and kidney cancer were among the first to show dramatic responses. Colorectal cancer with specific genetic features (microsatellite instability or mismatch repair deficiency) responds very well. Head and neck cancers, stomach cancer, bladder cancer, and Hodgkin lymphoma also benefit from immunotherapy. Ongoing trials are exploring immunotherapy in breast cancer, pancreatic cancer, and others.

Response depends on tumor characteristics. Tumors with high PD-L1 expression (often ≥50%) show better response to PD-1/PD-L1 inhibitors alone. Tumors with lower PD-L1 expression may benefit from combining immunotherapy with chemotherapy (chemoimmunotherapy) or other immunotherapy drugs. Your doctor performs testing on your tumor tissue (immunohistochemistry for PD-L1 expression, genetic sequencing) to predict which approach is most likely to work.

The Cost Advantage of Immunotherapy in India

One of immunotherapy’s biggest barriers globally is cost. In developed countries, a single cycle of PD-1/PD-L1 inhibitor costs $3,000-$5,000 (approximately ₹2,50,000-₹4,00,000). Indians often travel to India for treatment specifically for cost savings. In India, the same drugs from Indian manufacturers cost ₹80,000 to ₹2,50,000 per cycle depending on the drug and facility.

Generic immunotherapy drugs manufactured in India provide the same efficacy at significantly reduced cost. For example, nivolumab (Opdivo) in India costs approximately ₹1,20,000-₹1,80,000 per 100mg vial, compared to ₹3,00,000+ globally. Pembrolizumab (Keytruda) costs ₹1,00,000-₹2,00,000 per dose in India versus ₹4,00,000+ globally. A typical course of immunotherapy lasting 2 years costs ₹24-₹60 lakh in India, versus ₹1-₹2 crore globally.

Our Medical Team’s Perspective

When it comes to immunotherapy in india: how it works, costs, and who benefits (2026), early detection and a well-planned treatment strategy make a measurable difference in outcomes. Every case deserves a thorough review by a qualified oncology team before starting treatment.

— VICI Healthcare Medical Team

How Immunotherapy Is Administered

Immunotherapy drugs are given as intravenous (IV) infusions, typically once every 2-4 weeks depending on the specific drug. Each infusion takes 30 minutes to 1 hour. You sit in an outpatient clinic chair while the drug infuses into your arm. Most patients can go home the same day and resume normal activities. Some people experience fatigue or mild symptoms immediately after infusion, but these usually resolve within 24 hours.

Treatment continues as long as the cancer is responding and side effects are manageable. Some patients continue for 1-2 years, others for longer. Your doctor monitors you with regular CT scans and blood tests to track response. If the cancer stops responding or side effects become severe, treatment is stopped and alternative approaches are considered. The goal is to achieve durable response where the cancer remains controlled long-term.

Side Effects: Understanding Immune-Related Adverse Events

Immunotherapy side effects differ from chemotherapy. Instead of causing nausea, hair loss, and bone marrow suppression, immunotherapy causes immune-related adverse events (iRAEs). These occur because your immune system becomes overactive and can attack healthy tissues. Common iRAEs include inflammation of the lungs (pneumonitis), liver (hepatitis), colon (colitis), skin (rash), or thyroid. These can range from mild to severe.

Most iRAEs are manageable with monitoring and treatment. If you develop a rash, it’s often treated with topical steroids. Pneumonitis is treated with corticosteroids and sometimes hospitalization. Hepatitis or colitis are treated with corticosteroids and immunosuppressive drugs. Your oncology team monitors for iRAEs through regular blood tests and asks about symptoms at each visit. If iRAEs occur, they’re usually reversible upon stopping treatment or using immune-suppressing medications.

Success Rates and What to Expect

Immunotherapy response rates vary by cancer type and tumor characteristics. For PD-L1-positive lung cancers, response rates are 40-50%, meaning approximately half of patients show tumor shrinkage. For melanoma, response rates can exceed 40-50%. For colorectal cancers with microsatellite instability, response rates approach 40-50%. These rates are significantly better than chemotherapy alone for many cancers.

However, not all patients respond. Some patients show partial response (tumor shrinks but doesn’t disappear). Some progress despite immunotherapy. Duration of response also varies. Some patients achieve complete remission and remain cancer-free years after stopping immunotherapy. Others require ongoing treatment. Predictive tests like PD-L1 expression and tumor mutational burden help estimate likelihood of response, but aren’t perfectly accurate.

Combination Approaches: Immunotherapy Plus Other Treatments

Increasingly, immunotherapy is combined with chemotherapy (chemoimmunotherapy), targeted therapy, or other immunotherapy drugs. For patients whose tumors have low PD-L1 expression, chemoimmunotherapy often works better than immunotherapy alone. Combining immunotherapy with targeted therapy can also enhance responses in certain cancers. Two different immunotherapy drugs (targeting different immune checkpoints) can be combined for improved effect.

These combinations increase efficacy but also increase side effects. Your oncologist discusses the specific regimen recommended for your cancer, weighing benefits against risks. Combination approaches often lead to longer survival but require careful monitoring for iRAEs. Clinical trials exploring new combinations continue to evolve the field.

Immunotherapy in India: Access and Future

Several immunotherapy drugs are approved and available in India. Major cancer centers in Delhi, Mumbai, Bangalore, Pune, and other cities offer immunotherapy. State cancer institutes and government hospitals increasingly provide immunotherapy at subsidized costs. Many pharmaceutical companies have patient assistance programs helping patients access drugs when cost is a barrier.

The field is rapidly evolving. New immunotherapy drugs, combinations, and predictive biomarkers are emerging. India is able to access these advances and also a developer. Several Indian pharmaceutical companies are manufacturing immunotherapy drugs, and Indian clinical trials are testing new combinations. This expanding access and innovation make immunotherapy an increasingly available option for Indian cancer patients.

Key Takeaways Recap

Immunotherapy harnesses your immune system to fight cancer. In India, it costs ₹1-3 lakh per cycle, compared to ₹8-15 lakh globally. Immunotherapy (PD-1/PD-L1 inhibitors) for cancer in India: how it works, costs ₹1-3 lakh/cycle, which cancers respond, side effects, success rates.

Frequently Asked Questions

How do I know if my cancer will respond to immunotherapy?

Your doctor recommends immunotherapy based on cancer type and stage. Testing your tumor for PD-L1 expression (immunohistochemistry) and genetic features (tumor mutational burden, microsatellite status) helps predict response. However, these tests aren’t perfectly predictive. Some patients without high PD-L1 still respond, while some with high PD-L1 don’t. Your oncologist discusses the likely benefit for your specific situation and helps weigh benefits against risks.

Can I take immunotherapy if I have autoimmune diseases?

Generally, patients with autoimmune conditions (rheumatoid arthritis, lupus, etc.) are cautioned against immunotherapy because it can exacerbate their condition. However, some carefully selected patients have received immunotherapy with close monitoring. This is a discussion between you and your oncologist and rheumatologist. Having autoimmune disease doesn’t automatically exclude you, but it requires careful consideration.

What happens if immunotherapy stops working?

If your cancer stops responding to immunotherapy (progresses despite treatment), your oncologist explores other options. This might include switching to a different immunotherapy drug, trying chemotherapy, targeted therapy, or clinical trials of new combinations. Resistance to immunotherapy is an active research area with emerging solutions. The goal is to transition you to the next effective treatment before your condition deteriorates.

How long do I need to continue immunotherapy?

Treatment duration varies. Some patients continue for 1-2 years. Others continue longer if responding well. Treatment goals are discussed with your oncologist. Some patients achieve complete remission and stop treatment, remaining cancer-free afterward. Others require ongoing treatment to maintain disease control. Your response and tolerance determine the duration specific to your situation.

Is immunotherapy available on government health schemes in India?

Availability varies by state and hospital. Some government cancer institutes have immunotherapy available. Many state health schemes are slowly incorporating immunotherapy for select cancers. Additionally, pharmaceutical companies often have patient assistance programs helping patients access drugs. Speak with your hospital’s social worker about available options and financial assistance programs.

Sources & References

1. FDA approval summaries for PD-1/PD-L1 inhibitors in various cancers
2. Journal of Clinical Oncology: Immunotherapy efficacy in advanced cancers
3. National Comprehensive Cancer Network (NCCN): Immunotherapy Guidelines
4. European Society for Medical Oncology (ESMO): Immunotherapy in Cancer
5. Indian Society of Oncology: Immunotherapy availability and access in India